Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Macrogenics (MGNX) EBITDA (2016 - 2025)

Macrogenics (MGNX) has disclosed EBITDA for 14 consecutive years, with -$14.1 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 8.44% to -$14.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$74.6 million through Dec 2025, down 11.4% year-over-year, with the annual reading at -$74.6 million for FY2025, 11.4% down from the prior year.
  • EBITDA for Q4 2025 was -$14.1 million at Macrogenics, down from $16.8 million in the prior quarter.
  • The five-year high for EBITDA was $57.4 million in Q2 2023, with the low at -$66.7 million in Q1 2022.
  • Average EBITDA over 5 years is -$23.6 million, with a median of -$39.0 million recorded in 2021.
  • The sharpest move saw EBITDA plummeted 2670.99% in 2021, then surged 238.8% in 2023.
  • Over 5 years, EBITDA stood at -$58.1 million in 2021, then surged by 122.23% to $12.9 million in 2022, then tumbled by 456.65% to -$46.0 million in 2023, then soared by 66.49% to -$15.4 million in 2024, then grew by 8.44% to -$14.1 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$14.1 million, $16.8 million, and -$36.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.